Stellate Ganglion Block as Novel Treatment for Heart Failure Patients

Launched by MINA SOBHI SAID FAM · Feb 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a procedure called Stellate Ganglion Block as a new treatment option for patients with heart failure. Heart failure means that the heart is not pumping blood as well as it should, which can cause symptoms like shortness of breath and fatigue. The trial is looking for adults aged 18 to 70 who have moderate to severe heart failure, specifically those whose hearts are not pumping effectively (with a measurement called ejection fraction of 40% or less) and who are already taking the best medications for their condition.

Participants in this study can expect to undergo the Stellate Ganglion Block procedure, which involves a small injection near a group of nerves in the neck. This treatment aims to improve heart function and reduce symptoms. However, not everyone can join the trial; individuals with certain conditions, like active cancer, severe heart failure emergencies, or those who are pregnant, will not be eligible. The trial is currently recruiting participants, and it’s a chance to explore a potentially helpful new therapy for those struggling with heart failure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 : 70 years old.
• • NYHA Class III-IV Heart Failure.
• • Heart failure with a reduced ejection fraction (HFrEF) LVEF ≤ 40% calculated using 2D echocardiography and Biplane Simpson's .
• • Optimal tolerated Medical Therapy for Heart Failure.
• Exclusion Criteria:
• • Active Malignancy.
• • Acute heart failure including pulmonary edema or cardiogenic shock.
• • Severe, life-threatening non-cardiac disease.
• • Pregnancy.
• • Localized infection.
• • Coagulopathy or anticoagulated patients.
• • Refused this procedure.